# K182700: Nexstim Navigated Brain Therapy (NBT) System 2

- Pathway: 510(k) (Traditional)
- Applicant: Nexstim Plc
- Decided: Mar 22, 2019 after 176 days
- Product code: OBP (Transcranial Magnetic Stimulator)
- Device class: 2
- Regulation: 21 CFR 882.5805
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 8 generations back to DEN070003 (2008). 14 ancestors in all.
3 later devices descend from it; 1 cites it directly.
0 of 18 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K173620: Mag Vita TMS Therapy System w/Theta Burst Stimulation, Tonica Elektronik A/S (2018) Summary page 4.
- K171902: Nexstim Navigated Brain Therapy (NBT) System 2, Nexstim Plc (2017) Summary page 5.

## Most influential descendants
- K220177: Magnus Neuromodulation System (MNS) with SAINT Technology, Model Number 1001K (2022), 2 descendants of its own
- K260189: MagVenture Accelerated TMS (aTMS) Therapy System (2026), 0 descendants of its own
- K251449: BrainsWay Deep TMS System (2025), 0 descendants of its own

## Indications for use
Nexstim Navigated Brain Therapy (NBT®) System 2 is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.

Source page: https://510kreport.com/device/K182700
Methodology: https://510kreport.com/methodology